基于SEER数据库对不同分期阑尾癌患者的预后分析
Prognostic Analysis of Patients withDifferent Stages of Appendiceal CancerBased on SEER Database
DOI: 10.12677/ACM.2024.141184, PDF,   
作者: 刘晓辉, 刘恩瑞, 王立涛, 高 鹏*:青岛大学附属医院急诊外科,山东 青岛
关键词: 阑尾肿瘤TNM分期生存预后Appendiceal Cancer TNM Classification Survival Prognosis
摘要: 目的:探究各分期阑尾癌患者的生存预后,并根据各项临床病理参数分析其预后预测价值。方法:应用 美国SEER数据库中自2010年至2015年,接受阑尾切除手术且术后确诊为阑尾癌的患者共5176例。根据 所收集的患者信息,分别采取单因素及多因素Cox回归来分析影响阑尾癌患者预后的主要因素;并使用 Kaplan-Meier法绘制生存曲线;Log-rank检验分析来比较生存率差异。结果:文中所收集患者的5年总 体生存率为64.68%,中位生存时间为58个月,平均生存时间为57月。四分期的五年生存率表现为90.3% (I期)、74.2% (II期)、59.1% (III期)、35.1% (IV期);多因素Cox回归分析显示,性别(95%CI: 1.052~1.361, P = 0.006)、诊断年龄(95%CI: 1.128~1.722; P < 0.001)、人种(95%CI: 1.018~1.266; P = 0.023)、邻近 器官有无受累(95%CI: 0.015~0.124; P < 0.001)、分化程度(95%CI: 0.848~1.098; P < 0.001)、T (95%CI: 0.565~0.815; P < 0.001)、N (95%CI: 1.783~2.216; P < 0.001)、M (95%CI: 1.663~2.261; P < 0.001)、切除局部淋巴结数(95%CI: 0.336~0.918; P = 0.009)是影响阑尾癌患者生存预后的独立因素。 结论:伴随着TNM分期的增高,阑尾癌根治手术患者的总体生存率是逐渐降低的。性别、诊断年龄、人 种、分化程度、邻近器官有无受累、T、N、M及局部切除淋巴结数等参数是评估阑尾癌根治手术患者生 存预后的独立指标,为临床上不同分期阑尾癌患者预后的分析提供参考。
Abstract: Objective: To investigate the prognosis of patients with appendiceal cancer at different stages and analyze the prognostic value of clinicopathological parameters. Methods: A total of 5176 patients with appendiceal cancer who underwent appendectomy from 2010 to 2015 were collected by SEER software in the United States, and the prognostic factors of colorectal cancer patients were analyzed by univariate and multivariate Cox regression analysis, the survival curve of patients was drawn by Kaplan-Meier method, and the difference of survival rate was analyzed by Log-rank test. Results: The 5-year overall survival rate of 5176 patients with appendiceal cancer was 64.68%, the median survival time was 58 months, and the average survival time was 57 months. The 5-year survival rates of stage I, II, III, and IV were 90.3%, 74.2%, 59.1%, and 35.1%, respectively. Multivariate Cox regression analysis showed that gender (95%CI: 1.052~1.361; P = 0.006), age at diagnosis (95%CI: 1.128~7.722; P < 0.001), race (95%CI: 1.018~1.266; P = 0.023) , differentiation degree (95%CI: 0.848~1.098; P < 0.001), adjacent organ involvement (95%CI: 0.015~0.124; P < 0.001), T (95%CI: 0.565~0.815; P < 0.001), N (95%CI: 1.783~2.216; P < 0.001), M (95%CI: 1.663~2.261; P < 0.001), and the number of resected local lymph nodes (95%CI: 0.336~0.918; P = 0.009) were independent factors affecting the survival prognosis of patients with appendiceal cancer. Conclusions: With the increase of TNM stage I, II, III, and IV, the overall survival rate of patients with appendiceal cancer after radical surgery gradually decreases. In addition, gender, age at diagnosis, race, differentiation, involvement of adjacent organs, T, N, M, and the number of locally resected lymph nodes are independent indicators for evaluating the survival prognosis of patients with appendiceal cancer after radical surgery, which provides a reference for the prognosis analysis of patients with different stages of appendiceal cancer.
文章引用:刘晓辉, 刘恩瑞, 王立涛, 高鹏. 基于SEER数据库对不同分期阑尾癌患者的预后分析[J]. 临床医学进展, 2024, 14(1): 1270-1279. https://doi.org/10.12677/ACM.2024.141184

参考文献

[1] Liu, T., Mi, J., Wang, Y., et al. (2022) Establishment and Validation of the Survival Prediction Risk Model for Appendi-ceal Cancer. Frontiers in Medicine, 9, Article 1022595. [Google Scholar] [CrossRef] [PubMed]
[2] Patel, S.H., Bihlmeyer, S., Eggenberger, J.C., Shanker, B.A. and Cleary, R.K. (2022) Locally Advanced Perforated Appendi-ceal Cancer: Case Report and Review. Clinical Case Reports, 10, e05349. [Google Scholar] [CrossRef] [PubMed]
[3] Orchard, P., Preece, R., Thomas, M.G., et al. (2022) Demographic Trends in the Incidence of Malignant Appendicealtumours in England between 1995 and 2016: Population-Based Analysis. BJS Open, 6, zrac103. [Google Scholar] [CrossRef] [PubMed]
[4] Marmor, S., Portschy, P.R., Tuttle, T.M. and Virnig, B.A. (2015) The Rise in Appendiceal Cancer Incidence: 2000-2009. Journal of Gastrointestinal Surgery, 19, 743-750. [Google Scholar] [CrossRef] [PubMed]
[5] Singh, H., Koomson, A.S., Decker, K.M., et al. (2020) Continued Increasing Incidence of Malignant Appendiceal Tumors in Canada and the United States: A Population-Based Study. Cancer, 126, 2206-2216. [Google Scholar] [CrossRef] [PubMed]
[6] 许明芳, 蹇丹, 彭红, 等. 原发性阑尾黏液腺癌30例临床特征分析[J]. 解放军医学杂志, 2021, 46(1): 42-48. [Google Scholar] [CrossRef
[7] 罗欢, 李建新, 苟豪贤, 等. 原发性阑尾肿瘤的临床特征、治疗及预后影响因素分析[J]. 中国普外基础与临床杂志, 2023, 30(6): 721-727. [Google Scholar] [CrossRef
[8] 李华. 腹腔热灌注化疗应用于阑尾黏液腺癌的研究进展[J]. 检验医学与临床, 2022, 19(17): 2433-2436. [Google Scholar] [CrossRef
[9] Milovanov, V., Sardi, A., Ledakis, P., et al. (2015) Systemic Chemotherapy (SC) before Cytoreductive Surgery and Hyperthermicintraperitoneal Chemotherapy (CRS/HIPEC) in Patients with Peritoneal Mucinous Carcinomatosis of Appendiceal Origin (PMCA). European Journal of Surgical Oncology, 41, 707-712. [Google Scholar] [CrossRef] [PubMed]
[10] Inoue, A., Murata, K., Komori, T., et al. (2021) Open versus Lapa-roscopic Surgery for Primary Appendiceal Tumors: A Large Multicenter Retrospective Propensity Score-Matched Cohort Study in Japan. Surgical Endoscopy, 35, 5515-5523. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, Y., Geng, Y. and Hu, W. (2022) Survival and Prognostic Factors for Postoperative Primary Appendiceal Cancer: A Retro-spective Cohort Study Based on the Surveillance, Epidemiology, and End Results Database. Journal of Gastrointestinal Oncology, 13, 1433-1443. [Google Scholar] [CrossRef] [PubMed]
[12] Djadou, T.M., Poh, K.S., Yellinek, S., et al. (2023) Cytoreductive Surgery and Hyperthermic Peritoneal Chemotherapy in Appendiceal and Colorectal Cancer: Out-comes and Survival. The American Surgeon, 89, 5757-5767. [Google Scholar] [CrossRef] [PubMed]
[13] Webb, C., Chang, Y.H., Pockaj, B.A., Gray, R.J., Stucky, C.C. and Wasif, N. (2021) Lymph Node Positivity and Association with Long-Term Survival for Different Histologies of Appendiceal Cancer. Journal of Surgical Oncology, 124, 88-96. [Google Scholar] [CrossRef] [PubMed]
[14] Rozich, N.S., et al. (2021) Women Survive Longer than Men Undergoing Cytoreductive Surgery and HIPEC for Appendiceal Cancer. PLOS ONE, 16, e0250726. [Google Scholar] [CrossRef] [PubMed]
[15] Mason, J.B., Habermehl, T.L., Underwood, K.B., et al. (2022) The Interrelationship between Female Reproductive Aging and Survival. The Jour-nals of Gerontology: Series A, 77, 75-83. [Google Scholar] [CrossRef] [PubMed]
[16] da Luz, F.A.C., Nascimento, C.P., Marinho, E.D.C., et al. (2023) Survival Differences between Women and Men in the Non-Reproductive Cancers: Results from a Matched Analysis of the Surveillance, Epidemiology, and end-Results Program. Frontiers in Public Health, 10, Article 1076682. [Google Scholar] [CrossRef] [PubMed]
[17] Votanopoulos, K.I., et al. (2015) Peritoneal Surface Disease (PSD) from Appendiceal Cancer Treated with Cytoreductive Surgery (CRS) and Hyperther-micintraperitoneal Chemotherapy (HIPEC): Overview of 481 Cases. Annals of Surgical Oncology, 22, 1274-1279. [Google Scholar] [CrossRef] [PubMed]
[18] Stewart, J.H., et al. (2006) Appendiceal Neoplasms with Perito-neal Dissemination: Outcomes after Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. Annals of Surgical Oncology, 13, 624-634. [Google Scholar] [CrossRef] [PubMed]
[19] Freudenberger, D.C., et al. (2023) Race and Ethnicity Impacts Overall Survival of Patients with Appendiceal Cancer Who Undergo Cytoreductive Surgery with Hyperthermic Intraper-itoneal Chemotherapy. Cancers, 15, Article 3990. [Google Scholar] [CrossRef] [PubMed]
[20] Janczewski, L.M., et al. (2023) Survival Outcomes Used to Validate Version 9 of the American Joint Committee on Cancer Staging System for Appendiceal Cancer. CA: A Cancer Journal for Clinicians, 73, 590-596. [Google Scholar] [CrossRef] [PubMed]
[21] 中国医师协会结直肠肿瘤专业委员会. 中国阑尾肿瘤多学科综合治疗专家共识(2021版) [J].中华结直肠疾病电子杂志, 2021, 10(3): 225-231. [Google Scholar] [CrossRef